Toxicogenomics Applications

As toxicogenomics continues to move forward, it will likely seem at times as if progression is standing still and at other times advancing quickly. In order to advance, key milestones will require coordination across fields and disciplines, so progress is likely to be incremental. Within the next 5 years, it is likely that toxicogenomics will move slowly forward. Biologists will continue to impact the field of informatics, and what constitutes a pathway will be better defined and begun to be standardized universally. In addition, the work of discovery and validation of prodromal biomarkers for a variety of toxicities and diseases will continue to evolve. The advance in technology will no doubt come with reduced cost per sample for analysis and will enable simultaneous probing of genetic, genomic, proteomic,and metabolomic events. In the regulatory environment, toxicogenomics biomarker data will routinely be used to better inform the risk assessment from in vitro and in vivo test systems. The acceptance of modified test systems will eventually lead to an impact that minimizes animal testing and allows efficient modelling from human in vitro–based assays and ultra lowdose testing of human subjects to extrapolate and inform toxicity predictions. These models will eventually lead way to predictive in silico models that can help reduce use of animals and cost of experiments conducted to assess hazard and risk.

Toxicogenomics has emerged as a new and exciting technology that could potentially revolutionize drug discovery and development. Thus far, it has been shown that Toxicogenomics could be successfully implemented to predict toxicity liability and the toxicity mechanisms in the drug discovery- development continuum. In addition, it is believed that Toxicogenomics could offer additional added values compared to conventional toxicology methods. However, there are still many caveats and challenges as described above which remain to be resolved before its full potential could be realized. Nevertheless, the proper exploitation of this technology, in conjunction with the current development of proteomics and metabolomics, appropriate comparison of toxicogenomics and conventional toxicology, clinicopathology biomarkers and pathological endpoints, could potentially offer a competitive advantage to pharmaceutical companies in their drug discovery and drug development paradigm.

  • Screening tools to predict toxicity & targets
  • Identification of biomarkers
  • Hypothesis generation to aid in the determination of MOA(s)
  • Hypothesis testing
  • Identifying critical targets or pathways
  • Quantifying interspecies difference
  • Uses in dose-response analyses
  • SAR/QSAR models
  • Use of toxicogenomics information directly as a POD
  • Toxicogenomics in regulatory application

Related Conference of Toxicogenomics Applications

Toxicogenomics Applications Conference Speakers